Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.
about
Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopyPeptide and protein-based inhibitors of HIV-1 co-receptorsFormulation, pharmacokinetics and pharmacodynamics of topical microbicides.The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasmaDual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysisFormulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV preventionTopical prophylaxis for HIV prevention in women: becoming a reality.A potent combination microbicide that targets SHIV-RT, HSV-2 and HPVMultipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicidesUpdate on microbicide research and development - seeking new HIV prevention tools for women.Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionPhase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized TrialThe nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.Decreasing herpes simplex viral infectivity in solution by surface-immobilized and suspended N,N-dodecyl,methyl-polyethylenimine.A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.HIV PrEP Trials: The Road to Success.Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010).Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation propertiesA novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.Methodological lessons from clinical trials and the future of microbicide research.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration.Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.On-demand microbicide products: design matters.The Effect of Commonly Used Excipients on the Epithelial Integrity of Human Cervicovaginal Tissue.Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.First real success for anti-HIV gel: a new start for HIV microbicides?Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.
P2860
Q28538105-23150BB4-072B-4605-A75D-47B81819F9B7Q30352117-A0137637-8CED-451C-9245-06C04CF1F65FQ30412592-DCEBB6D9-C924-47A1-930A-71D0B6B5A4E1Q30414890-1DAC9ADE-DAAE-4265-9C82-E4D1AEA3A154Q30499941-127D8480-0745-45D5-AAA6-319DB4FE6395Q33598736-2F35BEE2-FFBB-4C34-B072-759D93128FD4Q33821090-6D0DCD27-F4E1-4642-9E2E-A5E8F6357C34Q33923694-A7F76764-AE83-4F1E-BE91-7CE91DFAE874Q34085477-9B4FA650-B3D8-4A09-8F7E-5471AC6E29F1Q35002085-99B97377-36CD-44A2-90C6-12103FA39821Q35031133-1B972796-8E94-4B4B-AE58-953FDBFCE721Q35150470-A2DF1AE9-61ED-419C-B5DE-5E8894486523Q35155093-8E101D2C-6A44-41AF-9E6A-C0F82B3A92F1Q35563416-4EE745B6-E83F-490B-B2C6-1154B2289A6BQ35659488-EE96B097-ED54-4C1C-8667-AC2EB7560028Q35746066-42B02012-E1F8-4400-8465-14939365DD7CQ35958928-C5944D1E-4859-4168-B29C-E1C8205F7563Q36033871-2A7EC02A-0407-40BF-BF38-9280C5DF135CQ36143276-8CFF6754-4764-4795-9306-54EBA26FED1CQ36166932-C133DAD4-25AE-42BA-9CD6-F23FBEF9B1AAQ36359133-36C33C99-606D-4A09-BCD5-06CF20C973F4Q36641494-A021B132-C42F-49AB-9420-84EC81974559Q37293488-1D15390E-AC12-4132-AC5E-2961A1764A6EQ37438644-06C956D9-59C5-46A4-895F-2F9FA682F7A8Q37458024-5D7FE542-72F4-4FF4-AEC4-8E922FFAF3AEQ37520083-623339F0-C294-46EC-AD8F-FF1A2359B893Q37543238-0790A3BD-7195-4C8C-898C-079CB372C01EQ37597118-0A6EFB4C-E207-4CEE-84B7-C91A61380F12Q37980177-E580BD84-2746-4476-89AE-6277993D12C8Q37990037-FE659A49-52D3-4010-81B5-A72A7F218825Q38062882-68579806-DB87-4777-AEB8-B2E015EE12F0Q38574172-0DD79548-90AA-4730-A992-72CA9F70415DQ38636239-00F8023F-993F-4B4D-A35A-E45398D2C8E4Q39265131-10DCCD92-C039-4537-8BED-83F67D3E1E79Q39356290-8CA955AB-DCA8-409C-9D5F-3E3BCC5B7796Q39407355-67E05CF2-F76D-408F-A19F-74F103CBD482Q40465731-4930EF8E-CCDB-433E-BC19-58E7F8154F2EQ41339468-0C5A6D2E-FB77-4F8F-A81C-B8FA2C9A9564Q42785516-57532101-3FEC-414B-9890-1CB2B5227B27Q51166879-310FBFCD-FEAE-48B2-9AE5-5906A3C61288
P2860
Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@en
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@nl
type
label
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@en
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@nl
prefLabel
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@en
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@nl
P2093
P1476
Pharmacokinetics of 2 dapiviri ...... e-based universal placebo gel.
@en
P2093
Annalene M Nel
Joseph W Romano
Paulina E Kaptur
Sepideh Habibi
Shanique C Smythe
P304
P356
10.1097/QAI.0B013E3181E3293A
P407
P577
2010-10-01T00:00:00Z